The results from our current study are in accordance with those of the previous study in gastric cancer at the early stage, which demonstrated that HER-2/neu could serves as a prognostic marker to predict the risk of poor outcome (P = 0.005).31 The gene discussed is ERBB2; the disease is gastric cancer.